Coronary Stents in Patients with ST-Elevation Myocardial Infarction and Chronic Kidney Disease Undergoing Primary Percutaneous Coronary Intervention|RISS 상세보기

다국어 초록 (Multilingual Abstract)

Background and Objectives: Chronic kidney disease (CKD) is associated with poor outcomes after percutaneous coronary intervention (PCI).
We sought to compare different coronary stents used during primary PCI in patients with ST-elevation myocardial infarction (STEMI) and CKD.
Subjects and Methods: We selected 2408 consecutive STEMI patients with CKD (estimated glomerular filtration rate <60 mL/min/1.73 m 2 )undergoing primary PCI and divided them into 5 groups based on the type of stent implanted: 1) bare metal stent (BMS), 2) paclitaxel-eluting stent (PES), 3) sirolimus-eluting stent (SES), 4) zotarolimus-eluting stent (ZES), or 5) everolimus-eluting stent (EES). The study end-point was the number of major adverse cardiac events (MACE) at 12 months.
Results: There was no significant difference in the incidence of 12-month myocardial infarction, target lesion revascularization, or target vessel revascularization between stent groups; however, the overall rate of repeat revascularization differed significantly between groups.
All-cause death differed significantly among the groups. The incidence of 12-month MACE in BMS, PES, SES, ZES, and EES was 8.3%, 9.8%,8.6%, 5.5%, and 2.6%, respectively (p<0.001). Kaplan-Meier analysis did not show a significant differences in 12-month MACE-free survival among the groups (log-rank p=0.076). This finding remained the same after adjusting for multiple confounders (p=0.147).
Conclusion: Any of the 5 stents can be used to treat STEMI patients with CKD undergoing primary PCI; all have similar risk of 12-month MACE. This result is hypothesis-generating and warrants further evaluation with a long-term randomized study.

번역하기

참고문헌 (Reference)

1 이기홍, "한국인 급성 심근경색증 등록 연구에서 성별에 따른 임상적 특징과 초기 치료의 차이" 대한심장학회 37 (37): 64-71, 2007

2 Best PJ, "The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions" 39 : 1113-1119, 2002

3 Charytan D, "The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease" 70 : 2021-2030, 2006

4 Kirtane AJ, "Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies" 119 : 3198-3206, 2009

5 Naidu SS, "Renal insufficiency is an independent predictor of mortality after percutaneous coronary intervention" 92 : 1160-1164, 2003

6 Dumaine R, "Prognostic significance of renal insufficiency in patients presenting with acute coronary syndrome (the Prospective Multicenter SYCOMORE study)" 94 : 1543-1547, 2004

7 Khurshid Ahmed, "Prognostic Impact of Baseline High-Sensitivity C-Reactive Protein in Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention Based on Body Mass Index" 대한심장학회 42 (42): 164-172, 2012

8 Szczech LA, "Outcomes of patients with chronic renal insufficiency in the bypass angioplasty revascularization investigation" 105 : 2253-2258, 2002

9 Barthelemy O, "One year clinical outcomes in patients with chronic kidney disease treated by percutaneous coronary intervention with drug-eluting stent" 147 : 307-, 2011

10 Hachinohe D, "Management of non-ST-segment elevation acute myocardial infarction in patients with chronic kidney disease (from the Korea Acute Myocardial Infarction Registry)" 108 : 206-213, 2011